Methotrexate is the most common disease-modifying antirheumatic drug used in the treatment of rheumatoid arthritis. The side effects which are known to occur include pancytopenia, hepatic dysfunction, pulmonary toxicity, and acute renal failure. This is a case report of a patient who presented with florid manifestations of methotrexate toxicity which happened due to mistaken overdosing of methotrexate which had been prescribed to her for rheumatoid arthritis.
• Systemic examination revealed no abnormality • Her hemoglobin was 9.9 g/dl, and total leukocyte count and platelet count were 1100/mm 3 and 6000/mm 3 , respectively. Peripheral blood smear showed normocytic, normochromic cells with severe thrombocytopenia and leukopenia. The kidney and liver function tests were normal.
On detailed history, the patient divulged that she had been prescribed tablet methotrexate 7.5 mg which she had been taking daily for the past 15 days by mistake, thinking that she had prescribed to take it daily.
She was diagnosed as a case of methotrexate-induced pancytopenia. The management included leucovorin, granulocyte colony-stimulating factor, methylprednisolone, and aggressive care for infection prevention. The patient was put in an isolation area of the medical intensive care unit, and broad-spectrum antibiotics such as piperacillin-tazobactam and clindamycin were started. Blood products including platelets were also transfused. The medications for diabetes and hypertension were continued as earlier.
Introduction
M ethotrexate is a drug which is a folate antimetabolite and inhibits the enzyme dihydrofolate reductase, thereby inhibiting the DNA synthesis process. It has been extensively used as a disease-modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis. The dosage used varies from 7.5 to 30 mg/week. There have reports of methotrexate poisoning and overdose, but most of these have been among dermatological patients, where methotrexate finds much use even in high doses. This case is being reported because of the unique circumstances under which the patient suffered methotrexate overdose and finally succumbed to it.
Case Report
A 60-year-old patient presented to the outpatient department of general medicine at our hospital with complaints of difficulty in opening the mouth, pain in the mouth, and ulcer on the lips for the past 9 days. The complaints were severe enough to prevent her from having any food. There were no other complaints. The patient was a known diabetic taking oral medications and no other comorbidities for her condition. On taking the history, it was ascertained that she had joint pain for the past 2 years and had consulted many doctors for it. She had recently been diagnosed as a case of rheumatoid arthritis and started with antirheumatoid treatment. 
Discussion
The patient had been prescribed methotrexate as a DMARD for the treatment of rheumatoid arthritis, where it has shown excellent results and is the drug of choice in low doses. [1] The side effects include mucositis, hepatotoxicity, nephrotoxicity, and myelosuppression. Patients on methotrexate need regular laboratory tests to monitor their kidney function, liver function, and blood counts. The American College of Rheumatology has guidelines for following patients on methotrexate with routine blood tests consisting of a complete blood count, liver function test, and creatinine. If the patient has been on the medication for more than 6 months, blood tests are required to be done every 12 weeks. However, in the presence of comorbidities or abnormal laboratory results, more frequent monitoring is warranted. [2] The side effects of methotrexate overdose have been documented with all the findings mentioned above but have been more in patients who are receiving higher doses for dermatological conditions such as psoriasis or malignancies. Deranged renal function is also responsible for increasing the chances of the patient suffering overdose.
This case demonstrates the need of effective and repetitive communication with the patient whenever a drug such as methotrexate is prescribed because although it has been shown to have a great drug as a DMARD, the side effects can manifest and be life-threatening if they occur [ Figures 1 and 2] . The treatment involves the administration of leucovorin, granulocyte colony-stimulating factor, blood products, and meticulous infection prevention measures.
Kivity et al. studied 28 patients presenting with low-dose methotrexate overdose and found pancytopenia to be the most common presenting feature (78%). The risk factors included acute renal failure, hypoalbuminemia, and concurrent use of drugs known to interact with methotrexate and dose errors. However, the serum methotrexate levels did not correlate with the degree of neutropenia or thrombocytopenia, and it did not even differ in patients who died of toxicity or survived it. All the patients, who died, died as a result of sepsis resulting from myelosuppression. [3] In another case study by Calvo-Romero, it was found that pancytopenia due to low-dose methotrexate therapy is more likely to occur in the presence of renal impairment. [4] Mori et al. studied 40 cases of methotrexate-receiving patients who had developed myelosuppression. The most common factors responsible for the development of myelosuppression as reported by them were inadequate or no use of folic acid supplements (P < 0.001), concurrent medications (P < 0.001), and low renal function (P = 0.002). They also concluded that myelosuppression can occur at any time during the treatment, and the severity of the disease was not dependent on the dosage of methotrexate. [5] There have been a few other reports also mentioning methotrexate toxicity, which had been prescribed for various reasons. [6] [7] [8] [9] This patient had been prescribed methotrexate 7.5 mg to be taken once a week which was apparent from the prescriptions that she had with her. However, she had been taking it daily for the past 10 days before landing up in her present state. Singh and Handa reported a similar case where toxicity occurred as a result of prescription error which was similar to this where the patient misunderstood the frequency of doses that she had to take. [10] Grissinger reported one such similar case, where the patient took the drug daily instead of weekly. [11] The case makes the need for proper and repeated counseling of the patients regarding the dosage of drugs 
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